Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue (GHS). Early pharmacology characterized it as a potent agonist in the growth hormone secretagogue receptor pathway, with research focused on growth-hormone release, receptor selectivity, pharmacokinetics, and signaling. It is mechanistically distinct from growth hormone-releasing hormone (GHRH) analogs such as CJC-1295 and tesamorelin.
What Is Ipamorelin?
Ipamorelin is a five-residue synthetic peptide originally described as Aib-His-D-2-Nal-D-Phe-Lys-NH₂. In preclinical studies it stimulated growth-hormone (GH) release in pituitary-cell and animal models. Researchers classified it within the growth hormone secretagogue family rather than the GHRH-analog family.
The Growth Hormone Secretagogue Receptor Pathway
Growth hormone secretagogues act through the growth hormone secretagogue receptor, commonly designated GHS-R1a, a G-protein-coupled receptor also activated by the endogenous peptide ghrelin. Research on this receptor established a signaling pathway distinct from the GHRH receptor pathway. GHRH receptors primarily signal through adenylyl cyclase and cAMP, whereas GHS-R signaling involves pathways including phospholipase C and intracellular calcium signaling.
Why Ipamorelin Is Different From GHRH Analogs
Tesamorelin and CJC-1295 are studied as GHRH-receptor agonists or analogs. Ipamorelin instead belongs to the GHS/GHRP class and engages the ghrelin/GHS receptor pathway. Both pathways can influence pituitary GH release, but they begin at different receptors and use different intracellular signaling mechanisms. This distinction is useful when comparing GH-axis compounds in laboratory research.
Selectivity in Early Pharmacology
A frequently cited 1998 study described ipamorelin as a selective GH secretagogue. In animal experiments, ipamorelin produced GH release while ACTH and cortisol responses were not significantly different from those observed after GHRH under the conditions tested. Those findings were preclinical and should not be generalized beyond the experimental models in which they were observed.
Human Pharmacokinetic and Pharmacodynamic Research
A controlled dose-escalation study in healthy male volunteers examined ipamorelin pharmacokinetics and GH responses. The investigators reported dose-proportional pharmacokinetics, an approximately two-hour terminal half-life, and an episodic GH response after intravenous infusion. The study was designed to characterize pharmacokinetic/pharmacodynamic relationships; it does not establish therapeutic benefit or general clinical use.
Ipamorelin and Ghrelin-Receptor Research
The discovery of ghrelin as an endogenous ligand for GHS-R helped place synthetic secretagogues into a broader biological context. Subsequent research has examined ghrelin and synthetic GHS compounds as tools for studying pituitary signaling, receptor pharmacology, gastrointestinal physiology, and other receptor-mediated processes. Ipamorelin has also appeared in preclinical studies investigating ghrelin-receptor-related gastrointestinal motility.
What Researchers Study
Research involving ipamorelin has included receptor selectivity, structure-activity relationships, GH secretory responses, pharmacokinetics, pharmacodynamics, and comparisons with other GHRPs and GHS compounds. These studies illustrate how small changes in peptide structure can alter potency, selectivity, disposition, and receptor-mediated effects.
Research Context
Ipamorelin is best understood as a research compound within the synthetic growth hormone secretagogue family. Its scientific interest comes from its interaction with the GHS-R pathway and from comparative research examining how that pathway differs from GHRH-receptor signaling. A clear distinction between mechanistic research and established clinical use is important when interpreting the literature.
Explore Ipamorelin for Research
Interested in working with Ipamorelin in your laboratory research? View Azyven Research Ipamorelin →
Available strengths and product information can be found on the product page.
For laboratory research use only.
References
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552. PMID: 9849822.
Gobburu JVS, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999. doi:10.1023/A:1018955126402. PMID: 10496658.
Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083–1092. doi:10.1080/004982598238976. PMID: 9879640.
Smith RG, et al. Growth hormone secretagogue receptor family members and ligands. Endocrine. 2001;14(1):9–14. doi:10.1385/ENDO:14:1:009. PMID: 11322507.
Malagelada JR, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics. 2009. doi:10.1124/jpet.108.149211. PMID: 19289567.